For patients with recurrent ovarian cancer, trebananib did not improve overall survival
the ONA take:
Amgen has announced secondary endpoint results from its TRINOVA-1 study that investigated trebananib plus paclitaxel for the treatment of patients with recurrent ovarian cancer.
The combination therapy did not show a statistically significant improvement in overall survival compared with placebo plus paclitaxel. The TRIANOVA-1 study is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial that evaluated trebananib in combination with weekly paclitaxel in women with epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Researchers randomly assigned patients to receiver either trebananib 15mg/kg intravenously weekly plus paclitaxel 80mg/m2 intravenously weekly for 3 weeks for 4-week cycles or placebo plus paclitaxel 80mg/m2 intravenously weekly for 3 weeks for 4-week cycles.
Amgen previously announced positive primary endpoint results that showed a statistically significant improvement in progression-free survival in the trebananib group, but secondary endpoint results showed a median overall survival of 19.3 months among those who received trebananib and 18.3 months among those who received placebo.
Despite the disappointing results, trebananib is also being studied in other combinations for the same three cancers. Trebananib is an investigational peptibody that ultimately inhibits angiogenesis, thereby causing cancer cell death.
Results from TRINOVA-1 study that investigated trebananib plus paclitaxel for ovarian cancer.
Amgen today announced the top-line secondary endpoint results of overall survival from the Phase 3 TRINOVA-1 trial in women with recurrent platinum-resistant ovarian cancer.
The study, which evaluated trebananib plus paclitaxel versus placebo plus paclitaxel, did not demonstrate a statistically significant improvement in overall survival. Median overall survival was 19.3 months in the trebananib arm versus 18.3 months in the control arm. The data will be submitted to a future medical conference and for publication.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- Screening Recommendations for Children with Common Cancer Predisposition Syndromes
- Significance of Prostate Cancer Treatment-Related Factors Differ in Black, White Men
- Superior Tolerability, Efficacy With Alectinib in Treatment-Naïve ALK-poistive NSCLC
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Lack of Transfusion Services a Barrier to Hospice Care for Patients With Blood Cancers
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Ethnic Differences, Cultural Barriers Negatively Impact Mammography Follow-up Among Asian Ethnic Groups
- Study Questions Safety of E-cigarettes vs Regular Tobacco Cigarettes
- Changes in Pulmonary Function Tests in Breast Carcinoma Patients Treated With Locoregional Post-mastectomy Radiotherapy: Results of a Pilot Study
- Increases in Liver Cancer Incidence Influenced by Higher Rates of Comorbidities
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|